Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

Phase 2TerminatedNCT00200382

Rasim Gucalp27 enrolled

Overview

The purpose of this study is to develop new treatments that will hopefully result in the relief of symptoms and prolongation of life. For this reason, your doctors have offered you treatment with a new experimental drug called PS 341.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Non-small Cell Lung Cancer

Interventions

PS-341 (Velcade-drug)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have confirmed NSCLC (squamous, adeno- and large cell anaplastic carcinoma)stage III B or Stage IV. No prior chemotherapy regimen Patients must have adequate organ and marrow function Exclusion Criteria: * Untreated symptomatic brain metastasis Patients with known HIV positivity

Locations (5)

HealthAlliance Hospitals

Fitchburg, Massachusetts, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Albert Einstein Cancer Center

The Bronx, New York, United States

Jacobi Medical Center

The Bronx, New York, United States

Outcomes

Primary Outcomes

Response rate

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.